VNDA.O (VNDA.O) News
Track canonical SquawkNews coverage tagged to VNDA.O, VNDA.O. This hub brings together deduplicated headlines about market instrument, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Vanda Pharmaceuticals announces positive Phase III results for Hetlioz in delayed sleep-wake phase disorder
Vanda said its Phase III study met the primary endpoint with a 37.1-minute sleep onset shift versus placebo, with no new safety signals identified.
EARNINGS | Sep 29, 2026, 10:50 PM UTC
M
Vanda plans supplemental NDA filing for Hetlioz after Phase III win
Vanda said Phase III met its primary endpoint in delayed sleep-wake phase disorder, shifting sleep onset 37.1 minutes earlier than placebo (p=0.022), and plans to meet FDA and file an sNDA seeking a new indication.
EARNINGS | Sep 29, 2026, 10:46 PM UTC